PRNewsWire
30 Oct 2026, 11:46 UTC · 57m ago
AbbVie Reports Third-Quarter 2026 Financial Results
Impact · against what's priced in
The earnings beat and dividend hike are largely noise as the stock is already priced for aggressive growth and recent acquisitions. The slight guidance raise is actually lower than the $14.08 - $14.28 range the market already assumed based on prior expectations, limiting any positive catalyst effect.
- ABBV+0.00
Already priced in
- The price assumes
The $10.9 billion Apogee Therapeutics acquisition
The completion of the Apogee Therapeutics acquisition is explicitly listed as already absorbed by the current price.
What ABBV's price assumes · Sep 4
Top 1 mover · tap to explore
